Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemzar approved for breast cancer

Executive Summary

Lilly's Gemzar approved for use in combination with Bristol-Myers Squibb's Taxol for first-line treatment of metastatic breast cancer May 19. Clinical studies included in 1labeling show improvement in time to disease progression of 2.3 months over paclitaxel alone (5.2 versus 2.9 months). Overall response rate was 40.8% versus 22.1% for paclitaxel alone. Gemzar is already indicated for first-line non-small cell lung and pancreatic cancer...

You may also be interested in...



Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

Executive order calls for short-term and long-term study, broad consultation, coordination with allies.

Cosmetic And Personal Care Trademark Review 23 February, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel